The prevailing view in the literature has been that the Sulfs are negative regulators of tumor cell growth. A number of reports demonstrated that over-expression of Sulf-1
[28]–
[34] or Sulf-2
[32] in tumor cell lines inhibited growth factor signaling in response to several factors, including FGF-2, HB-EGF, and HGF. Moreover, the tumorigenicity of Sulf-overexpressing cells in immunocompromized mice was diminished
[31],
[32],
[34]. The negative effects of Sulfs on FGF-2 signaling are consistent with the known requirement for 6S on HSPGs in the FGF-2 signaling complex
[37]. These cell line findings have led to the suggestion that down-regulation of Sulfs could provide tumor cells with a growth advantage in certain settings. This model may have validity for the significant subset (two-thirds) of ovarian cancer cases
[28] and the minor subset (29%) of hepatocellular carcinoma cases
[30] in which
SULF1 expression is downregulated relative to that in normal tissue. However, the model is problematic for the sizeable subsets of several cancers which show increases in
SULF expression. Thus, for example,
SULF1 is upregulated in significant subsets of breast cancer
[38], pancreatic cancer
[31],
[39] () lung adenocarcinoma
[40] and hepatocellular carcinoma
[30], while
SULF2 is upregulated in multiple myeloma
[32], breast cancer and CNS cancers
[41].
To understand the significance of upregulated SULF expression in a cancer, we chose to focus on pancreatic adenocarcinomas because of clear evidence associating this cancer with canonical Wnt signaling, a signaling pathway known to be positively regulated by the Sulfs during development (see above). Consistent with the transcript expression data (), we found that both Sulfs were strongly expressed at the protein level by malignant epithelial cells in pancreatic adenocarcinoma. To facilitate investigation of these enzymes in pancreatic cancer, we examined SULF expression in a large panel of pancreatic adenocarcinoma cell lines and found widespread expression, especially of SULF2. We chose 4 lines for study, all of which expressed Sulf-2 protein and one of which expressed both Sulfs. Previous studies have shown that proliferation and survival of 3 of these (BxPC-3, HS766T and L3.6sl) depend on activated Wnt signaling [M. Pasca di Magliano and M. Hebrok, unpublished observations]. We showed that Wnt signaling was markedly inhibited by overexpressing recombinant sFRP-2 in these cell lines. Moreover, overexpression of catalytically inactive Sulf-2 in the same lines resulted in a marked inhibition of Wnt activity, and exposure of the cells to inactive Sulf-2 protein during culture inhibited both Wnt signaling and growth. These results are consistent with Wnt-ligand dependent growth of these cells (“autocrine Wnt signaling”), which is modulated by the extracellular Sulfs. It is plausible that the CFPAC-1 cell line, which was refractory to all of these treatments, carries an activating mutation in downstream elements of the Wnt signaling pathway that would bypass the need for extracellular Wnt ligands and the Sulfs. It should be noted that the Sulfs represent an additional example of an extracellular factor, which modulates Wnt signaling. However, in contrast to the extracellular Wnt antagonists such as DKK1 and sFRPs, which are suppressed in certain tumors, the Sulfs are upregulated in pancreatic adenocarcinomas and exert a positive effect on Wnt signaling. Here we demonstrate that the Sulfs enhance the activity of the Wnt pathway in tumor cells, a function demonstrated previously only in a developmental context.
Our results indicate that catalytically inactive Sulf-2 can act as a dominant-negative mutant. There are several plausible mechanisms to explain this effect. One is that inactive Sulf-2 acts as a “substrate trapping mutant” such that it competes with the active enzyme for binding to heparan sulfate substrates, thereby blocking the ability of the enzyme to alter the substrate and modulate Wnt interactions. A second explanation is based on the observation that certain sulfatases (e.g., arylsulfatase A), can form homo-oligomers
[42]. The Sulfs have the potential to form multimers due to their predicted coiled-coil structure
[22]. Thus, the catalytically inactive protein could interfere with the general activity when incorporated into a multimer. Thirdly, the inactive Sulf might displace the wild-type enzyme from a subdomain in the plasma membrane where it is normally targeted for optimal function. The cell surface associations of QSulf-1 and QSulf -2 are known to require the hydrophilic domains of the molecules, but the molecular details have not been worked out
[43].
To rigorously test the involvement of the Sulfs in Wnt signaling and tumor growth, we used lentiviral shRNA systems to silence Sulf-2 expression in four pancreatic adenocarcinoma cell lines. This approach contrasts with previous studies in which function of a Sulf was investigated in cancer cell lines by overexpressing it in cells that lacked it
[28]–
[34]. Sulf-2 silenced cells (BxPC-3, L3.6sl, HS766T) exhibited a decrease in DNA synthesis and an increase in apoptosis (BxPC-3, L3.6sl). Moreover, the silenced cells exhibited reduced Wnt activity by two criteria. Consistent with these findings, silenced cells showed a marked growth disadvantage in co-cultures with control cells. The dominant negative effects in the co-culture experiments with stably transfected HEK 293T cells () suggest that Sulf-2 can function in
trans, at least in the setting of artificial overexpression of the protein. Therefore, one might predict rescue of the silenced cells by the secreted Sulf-2 protein from control cells. We conclude that the rescue effect was at best partial, since the silenced cells grew at a slower rate than the control cells in the mixed culture.
The in vitro results were extended into a tumorigenesis model in nude mice by demonstrating that Sulf-2-silenced L3.6sl and BxPC-3 cells formed smaller tumors with time. Our evidence for the involvement of the Sulfs in the growth and tumorigenesis of pancreatic adenocarcinoma cells is most complete for Sulf-2. It remains to be seen what impact silencing Sulf-1 will have on a cell type that expresses this enzyme alone or in combination with Sulf-2 (e.g., HS766T cells). One might predict functional redundancy of the two enzymes based on the ability of either inactive Sulf to exert equivalent dominant negative effects (). Moreover, the two enzymes exhibit indistinguishable enzymatic activities against heparin/heparan sulfate in vitro
[22],
[43], although there is recent genetic evidence for cooperative activities
[26].
The present findings are the first to implicate the Sulfs as positive regulators of growth in a cancer, namely pancreatic tumors that are driven by autocrine Wnt signaling. Further xenograft experiments with cell lines and primary tumor cells, together with studies of mouse models of pancreatic adenocarcinoma
[44], are needed to test this proposed role for the Sulfs. Accumulating evidence indicates that a number of other cancers also depend on autocrine Wnt signaling for growth
[6]–
[8],
[15],
[45]–
[47]. Since
SULF upregulation has been found in a number of these cancers, the potential role of these enzymes in enhancing tumorigenesis deserves exploration in these systems. As extracellular enzymes, the Sulfs would be very attractive therapeutics targets for both small molecule and antibody approaches.